Goodsurance

Drug prices & Part D

About 140,000 Wellcare Part D Members Were Dropped Mid-Year After Small New Premiums Were Added to Their Previously Free Plans

KFF Health News found that Wellcare terminated tens of thousands of drug plan members in April 2026 when minimal monthly premiums went unpaid, leaving many without prescription coverage and at risk for permanent Medicare drug enrollment penalties.

By the Goodsurance editorial teamSeptember 21, 2026

KFF Health News reported in July 2026 that Wellcare Health Plans terminated approximately 140,000 members of its Value Script prescription drug plan in April 2026 after introducing a monthly premium to a plan that had been free for years. Many members did not pay the new charge, prompting mid-year disenrollment across 26 states and Washington, D.C.

The premium amounts involved were small. In Nevada, some members owed as little as 8 dollars and 10 cents for three months of accumulated unpaid charges. One beneficiary in the KFF Health News reporting saw his monthly premium rise from zero to 3 dollars and 60 cents.

Wellcare dropped about 140,000 Part D members mid-year after adding small new premiums to formerly free plans, leaving many at risk for permanent Medicare drug penalties, KFF Health News found.

Wellcare said roughly 40,000 of those terminated may qualify for the federal Extra Help program, also called the Low-Income Subsidy, which can allow immediate re-enrollment in a Part D plan. The remaining members generally cannot rejoin a drug plan until the fall annual enrollment period for 2027 coverage, absent a qualifying special enrollment event.

The financial stakes of a coverage gap are real. Under Medicare rules, people who go 63 or more consecutive days without creditable prescription drug coverage face a permanent monthly surcharge added to their future Part D premiums. The reporting illustrated the exposure: one beneficiary faced approximately 1,800 dollars for a 90-day supply of a blood thinner without Part D coverage.

KFF Health News also noted that the annual notice of changes disclosing the new premium ran 21 pages, raising questions about whether members had a realistic opportunity to notice and act before being dropped.

In plain words

A Medicare drug plan called Wellcare Value Script dropped about 140,000 members in April 2026. This happened in the middle of the year, not at the usual end-of-year enrollment period.

The plan had cost nothing for years. Then Wellcare added a small monthly fee. Many people did not know about it or did not pay. So Wellcare removed them. Some owed only a few dollars total.

This is serious. Under Medicare rules, if you go 63 days or more without drug coverage, you get a permanent penalty added to your future monthly premiums. And without a drug plan, medicines can cost a lot. One person in the news story had to pay about 1,800 dollars for a 90-day supply of a blood thinner.

About 40,000 of the dropped members may qualify for Extra Help, a program for lower-income people that can let them rejoin a plan right away. Others must wait for open enrollment this October.

The notice that explained the new premium was 21 pages long.

Source: KFF Health News
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

MedPAC September Meeting Finds IRA Changes Improved Drug Affordability for Enrollees but May Be Accelerating Overall Medicare Part D Spending

Medicare's congressional advisory commission opened its new study cycle in September finding that Inflation Reduction Act drug benefit changes have helped individual beneficiaries while putting upward pressure on total program spending and future premiums.

September 20, 2026

Drug prices & Part D

Medicare's 2027 Part D Base Beneficiary Premium Will Be 41 Dollars and 33 Cents, Hitting the Inflation Reduction Act's Annual Cap

CMS set the 2027 Part D base beneficiary premium at 41 dollars and 33 cents in July, representing a 6 percent rise from the prior year and the maximum the IRA allows, a benchmark that shapes what drug plans charge as open enrollment approaches.

September 19, 2026

Drug prices & Part D

Federal Watchdog Adds Medicare Part D GLP-1 Overdispensing to Its Active Study List

The Office of Inspector General announced a new evaluation of GLP-1 prescribing patterns in Part D, as the Medicare obesity drug bridge program continues to attract enrollment.

September 17, 2026

Drug prices & Part D

Federal Subsidy That Has Held Down Standalone Medicare Drug Plan Premiums for Two Years Is Ending After 2026

CMS is closing the Part D Premium Stabilization Demonstration after 2026, and a KFF analysis warns that people with standalone prescription drug plans in traditional Medicare could face larger premium increases in 2027 than they have seen in recent years.

September 13, 2026

Drug prices & Part D

Medicare Part D Drug Spending Is Projected to Nearly Double by 2035, With GLP-1 Prescriptions as the Primary Driver

A KFF analysis of the 2026 Medicare Trustees Report projects annual Part D spending will climb from 181 billion dollars in 2025 to 346 billion dollars in 2035, a pace driven largely by surging use of GLP-1 drugs for diabetes and weight loss. The data arrives six weeks before open enrollment opens.

September 11, 2026

Drug prices & Part D

Face-to-Face Drug Price Talks Between Medicare and Manufacturers Close Today on 15 High-Cost Drugs

September 11 is the statutory deadline for in-person and virtual negotiation meetings in Medicare's third drug price negotiation cycle. Written offers are next, with a final CMS offer due September 30 and manufacturer responses due by November 1.

September 11, 2026